About the Program:
Program Overview:
The Advances in Chronic Hepatitis C: Management and Treatment program is a comprehensive, independent review of the 66th American Association for the Study of Liver Diseases Annual Meeting (AASLD 2015). This program consists of six components: (1) CME Internet Symposium: AASLD 2015 Expert Review: a 1.5 hour Internet symposium that features an overview and discussion of key presentations and posters, selected by the expert faculty discussants; (2) CME Internet Symposium: European Perspective on AASLD 2015: a 1-hour Internet symposium featuring Europe-based expert faculty reviewing and discussing key presentations with a focus
on management and treatment in the EU; (3) CME Internet Symposium: Brazilian Perspective on AASLD 2015: a 1-hour Internet symposium featuring Brazil-based expert faculty reviewing and discussing key presentations with a focus on management and treatment in Brazil; (4) Comprehensive Expert Review and Discussion of Key Presentations: an on-line, in-depth review of 8 of the key poster/presentations reviewed in the Internet symposium (5) Rapid-Fire Independent Review of AASLD 2015: a podcast that provides a brief, audio summary of the most essential data presented at the conference; and (6) From Conference To Clinic: Reviewing And Applying Data From AASLD 2015: case-based dinner meetings during which the key data are reviewed, discussed and applied to patient care.
The CME Internet Symposium: Brazilian Perspective on AASLD 2015 will provide a Brazilian focused review and discussion of the key studies on chronic hepatitis C presented at AASLD 2015. The expected result is that Brazil-based participants will not only gain an increased understanding of key data presented at AASLD 2015, they will also be better prepared to address their HCV patients’ health needs and provide optimal care, which should improve treatment and adherence, increase individualized care, reduce adverse effects and drug-drug interactions, and improve quality of life for people with chronic hepatitis C throughout Brazil.
All online components of the program can be accessed at www.viraled.com.
This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at AASLD 2015 and it is not sanctioned by the organizers of AASLD 2015.
Program Faculty:
Mário G. Pessoa, MD, PhD
Assistant Professor
Division of Gastroenterology and Hepatology
University of São Paulo School of Medicine
São Paulo, Brazil
|
Mauro Schechter, MD, PhD
Professor of Infectious Diseases
Department of Preventive Medicine
Federal University of Rio de Janeiro, Brazil
Rio de Janeiro, Brazil
|
Hugo Cheinquer, MD, PhD
Associate Professor of Gastroenterology and Hepatology
Universidade Federal do Rio Grande do
Sul School of Medicine
Porto Alegre, RS, Brazil
|
Educational Objectives:
After completing this activity, the participant should be better able to:
- Use in a clinical setting in Brazil, important findings from key studies on CHC diagnosis and treatment presented at AASLD 2015
- Employ the current treatment paradigms for CHC applicable in Brazil, including the studies and data presented at AASLD 2015 to improve patient care
- Discuss with patients and colleagues how the studies and data on newer therapies for CHC presented at AASLD 2015 affect appropriate planning of therapy for patients with CHC in Brazil
Release Date: December 15, 2015
Expiration Date: December 15, 2016
Estimated time to complete the AASLD 2015 Brazil Internet Symposium: 1 hour, 15 minutes
Media: Internet
Back to Top
Target Audience:
This activity is intended for physicians, physician assistants, advanced practice nurses, and other health care professionals in Brazil involved in the treatment and management of patients with HCV infection.
Accreditation Statement:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation:
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest:
Postgraduate Institute for Medicine (PIM) requires instructors,
planners, managers and other individuals who are in a position to
control the content of this activity to disclose any real or apparent
conflict of interest (COI) they may have as related to the content of
this activity. All identified COI are thoroughly vetted and resolved
according to PIM policy. PIM is committed to provideing its learners
with high quality CME activities and related materials that promote
improvements or quality in healthcare and not a specific proprietary
business interest of a commerical interest.
Hugo Cheinquer, MD, PhD
- Consulting Fees: BMS, Gilead, AbbVie, Janssen
- Fees for Non-CME/CE Services: BMS, Gilead, AbbVie, Janssen
- Contracted Research: Abbvie
Mario Pessoa, MD
- Consulting Fees: Abbvie, Roche, Janssen, BMS, Gilead, Merck
- Fees for Non-CME/CE Services: Abbvie, Roche, Janssen, BMS, Gilead, Merck
- Contracted Research: Abbvie
Mauro Schechter, MD
- Consulting Fees: Achillion, BMS, Gilead, Abbvie, Merck, Janssen, Roche
The planners and managers reported the following financial
relationships or relationships to products or devices they or their
spouse/life partner have with commercial interests related to the
content of these CME activities:
The following PIM staff serve as clinical content reviewers and/or
participate in planning CME/CE activities in a manner that may affect
content:, Judi Smelker-Mitchek, RN, BSN; Trace Hutchison,
PharmD; Samantha Mattiucci, PharmD, CCMEP; Jan Shultz, RN, MSN, CCMEP
and Patricia Staples, MSN, NP-C, CCRN hereby state that they or their
spouse/life partner do not have any financial relationships or
relationships to products or devices with any commercial interests
related to the content of this CME/CE activity of any amount during the past 12 months.
Instructions for Participation and Credit:
There are no fees for participating and receiving CME credit for this activity. During the period, December 15, 2015 through December 15, 2016, participants must read the learning objectives and faculty disclosures and study the educational activity.
PIM supports Green CME by offering your Request for Credit online. If
you wish to received acknowledgment of completing this activity, please
complete the post-test and evaluation on www.cmeuniveristy.com. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 10853.
Upon registering and successfully completing the post-test with a score
of 70% or better and the activity evaluation, your certificate will be
made available immediately. Processing credit requests online will
reduce the amount of paper used by nearly 100,000 sheets per year.
Disclosure of Unlabeled Use: This
educational activity may contain discussion of published and/or investigational
uses of agents that are not indicated by the FDA. The planners of this activity
do not recommend the use of any agent outside of the labeled indications.
The
opinions expressed in the educational activity are those of the faculty and do
not necessarily represent the views of the planners. Please refer to the
official prescribing information for each product for discussion of approved
indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired
information to enhance patient outcomes and their own professional
development. The information presented in this activity is not meant to
serve as a guideline for patient management. Any procedures,
medications, or other courses of diagnosis or treatment discussed or
suggested in this activity should not be used by clinicians without
evaluation of their patient's conditions and possible contraindications
on dangers in use, review of any applicable manufacturer's product
information, and comparison with recommendations of other authorities.
Supported by an independent educational grant from Gilead Sciences Medical Affairs.
This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings.
|